Parkinson's disease: Second of two parts

New England Journal of Medicine

Volumn 339, Issue 16, 1998, Pages 1130-1143

  Lang, Anthony E ^a,b,c   Lozano, Andres M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NICOTINIC AGENT; OPIATE ANTAGONIST;

CLINICAL FEATURE; DISEASE COURSE; HUMAN; NEUROSURGERY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SURGICAL APPROACH;

ANTIPARKINSON AGENTS; HUMANS; LEVODOPA; MODELS, BIOLOGICAL; PARKINSON DISEASE;

EID: 0032531924     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199810153391607     Document Type: Review

References (106)

1. Filion M, Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Res 1991;547:142-51.
2. Filion M, Tremblay L, Bedard PJ. Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys. Brain Res 1988;444:165-76.
3. Jenkins IH, Fernandez W, Playford ED, et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Ann Neurol 1992;32:749-57.
4. Hutchison WD, Lozano AM, Davis KD, Saint-Cyr JA, Lang AE Dos-trovsky JO. Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. Neuroreport 1994;5:1533-7.
5. Hutchison WD, Levy R, Dostrovsky JO, Lozano AM, Lang AE. Effects of apomorphine on globus pallidus neurons in parkinsonian patients. Ann Neurol 1997;42:767-75.
6. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganelia disorders. Trends Neurosci 1989;12:366-75.
7. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-5.
8. Parent A, Hazrati L-N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 1995;20:128-54.
9. Chesselet MF, Delfs JM. Basal ganglia and movement disorders: an update. Trends Neurosci 1996;19:417-22.
10. Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery 1995;37:680-6.
11. Lang AE, Lozano AM, Montgomery E, Duff J, Tasker R, Hutchinson W. Posteroventral medial pallidotomy in advanced Parkinson's disease. N Engl J Med 1997;337:1036-42.
12. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-83.
13. Idem. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39:29-36.
14. Idem. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39: 37-45.
15. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38: 771-7
16. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl] protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 1997;68:434-6.
17. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-7.
18. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease. Ann Neurol 1996;40:841-5.
19. Mäki-Ikola O, Kilkku O, Heinonen E. Effect of adding selegiline to levodopa in early, mild Parkinson's disease: other studies have not shown increased mortality. BMJ 1996;312:702.
20. The Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-25.
21. Fahn S. Is levodopa toxic? Neurology 1996;47:Suppl 3:S184-S195.
22. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-64.
23. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46:388-93. [Erratum, Neurology 1996;46:1787.]
24. Agid Y. Levodopa: is toxicity a myth? Neurology 1998;50:858-63.
25. Rajput AH, Uitti RJ, Offord KP. Timely levodopa (LD) administration prolongs survival in Parkinson's disease. Parkinsonism Relat Disord 1997;3:159-65.
26. Hely MA, Morris JGL, Reid WGJ, et al. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994;57:903-10.
27. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-8. [Erratum, Neurology 1998;50:838.]
28. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-9. [Erratum, Neurology 1997;49:1484.]
29. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48: 363-8.
30. Chase TN, Engber TM, Mouradian MM. Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease. Neurology 1994;44:Suppl 6:S15-S18.
31. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: a multicenter 5-year study. Eur Neurol 1997;37:23-7.
32. Bonnet A-M, Loria Y, Saint-Hilaire MH, Lhermitte F, Agid Y. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions? Neurology 1987;37:1539-42.
33. Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997;20: 523-30.
34. Golbe LI. Young-onset Parkinson's disease: a clinical review. Neurology 1991;41:168-73.
35. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39: 561-73.
36. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996;60:634-7.
37. Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48:369-72.
38. Djaldetti R, Baron J, Ziv I, Melamed E. Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology 1996;46:1051-4.
39. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-24.
40. Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov Disord 1994;9:2-12.
41. Greenamyre JT. Pharmacological pallidotomy with glutamate antagonists. Ann Neurol 1996;39:557-8.
42. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-8.
43. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990;40:340-5.
44. Blanchet PJ, Gomez-Mancilla B, Di Paolo T, Bédard PJ. Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? Fundam Clin Pharmacol 1995;9:434-42.
45. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996;69:497-501.
46. Mouradian MM, Juncos JL, Fabbrini G, Schlegel J, Bartko JJ, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiology mechanisms. Ann Neurol 1988;24:372-8.
47. Sage JI, Sonsalla PK, McHale DM, Heikkila RE, Duvoisin RC. Clin-ical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease. Adv Neurol 1990;53:383-6.
48. Hughes AJ, Bishop S, Kleedorfer B, et al. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years. Mov Disord 1993;8:165-70.
49. Horowski R, Obeso JA. Lisuride: a direct dopamine agonist in the symptomatic treatment of Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's disease. 2nd ed. rev. New York: Marcel Dekker, 1995:219-48.
50. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-9.
51. Idem. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-71.
52. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12:483-96.
53. 3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol 1996;69:541-4.
54. Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D. Benztropine versus clozapine for the treatment of tremor in Parkinson's disease. Neurology 1997;48:1077-81.
55. Bennett JP Jr, Landow ER, Dietrich S, Schuh LA. Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction. Mov Disord 1994;9:409-14.
56. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-7.
57. Evatt ML, Jewart D, Jancos JL. "Seroquel" (ICI 204,636) treatment of psychosis in parkinsonism. Mov Disord 1996;11:595. abstract.
58. Kurth MC, Adler CH, St Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 1997;48:81-7.
59. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-55.
60. Pappert EJ, Goetz CG, Niederman F, Ling ZD, Stebbins GT, Carvey PM. Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. Neurology 1996;47:1493-5.
61. Djaldetti R, Koren M, Ziv I, Achiron A, Melamed E. Effect of cisapride on response fluctuations in Parkinson's disease. Mov Disord 1995;10:81-4.
62. Metman LV, van den Munckhof P, Klaassen AAG, Blanchet P, Mouradian MM, Chase TN. Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease. Neurology 1997;49:711-3.
63. Carpentier AF, Bonnet AM, Vidailhet M, Agid Y. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996;46:1548-51.
64. Durif F, Vidailhet M, Bonnet AM, Blin J, Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995;45:1855-8.
65. Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y. Low-dose clozapine improves dyskinesias in Parkinson's disease. Neurology 1997;48:658-62.
66. Bonifati V, Fabrizio E, Cipriani R, Vanacore N, Meco G. Buspirone in levodopa-induced dyskinesias. Clin Neuropharmacol 1994;17:73-82.
67. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-6.
68. Miyawaki E, Meah Y, Koller WC. Serotonin, dopamine, and motor effects in Parkinson's disease. Clin Neuropharmacol 1997;20:300-10.
69. Richard IH, Kurlan R, Tanner C, et al. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Neurology 1997;48:1070-7.
70. Hurwitz TA, Calne DB, Waterman K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988;15:32-4.
71. Mayeux R, Stern Y, Mulvey K, Cote L. Reappraisal of temporary levodopa withdrawal ("drug holiday") in Parkinson's disease. N Engl J Med 1985;313:724-8.
72. Kuno S, Mizuta E, Yamasaki S. Neuroleptic malignant syndrome in parkinsonian patients: risk factors. Eur Neurol 1997;38:56-9.
73. Tariot PN, Schneider L, Porsteinsson AP. Treating Alzheimer's disease: pharmacologic options now and in the near future. Postgrad Med 1997;101:73-6.
74. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998;50:136-45.
75. Djaldetti R, Melamed E. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease. Ann Neurol 1996;390: 400-4.
76. Williams M, Wright S, Lloyd GK. Improved therapies for Parkinson's disease: life beyond dopamine D2/D3 receptor agonists. Trends Pharmacol Sci 1997;18:307-10.
77. The Parkinson Study Group. Effect of lazabemide on the progression of disability in early Parkinson's disease. Ann Neurol 1996;40:99-107.
78. Rascol O, Fran T, Blin O, et al. ABT-431, a selective D1 agonist has efficacy in patients with Parkinson's disease. Neurology 1997;48:Suppl: A269-A270. abstract.
79. Belluzzi JD, Domino EF, May JM, Bankiewicz KS, McAfee DA. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov Disord 1994;9:147-54.
80. Dewey RB Jr, Maraganore DM, Ahlskog JE, Matsumoto JY. Intranasal apomorphine rescue therapy for parkinsonian "off" periods. Clin Neuropharmacol 1996;19:193-201.
81. 2A receptor antagonists as new agents for the treatment of Parkinson's disease. Trends Pharmacol Sci 1997;18:338-44.
82. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol 1994;35:655-61.
83. Steiner JP, Hamilton GS, Ross DT, et al. Neurotrophic immunopnilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci U S A 1997;94:2019-24.
84. Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Mov Disord 1998; 13: 28-33.
85. 15O PET study. Brain 1997;120:1301-13.
86. Davis KD, Taub E, Houle S, et al. Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nat Med 1997;3:671-4.
87. Limousin P, Greene J, Pollak P, Rothwell J, Benabid AL, Frackowiak R. Changes in cerebral activity pattern due to subthalamic nucleus or internal pallidum stimulation in Parkinson's disease. Ann Neurol 1997;42: 283-91.
88. Koller W, Pahwa R, Busenbark K, et al. High-frequenty unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol 1997;42:292-9.
89. Benabid AL, Pollak P, Gao DM, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996;84:203-14.
90. Dogali M, Fazzini E, Kolodny E, et al. Stereotactic ventral pallidotomy for Parkinson's disease. Neurology 1995;45:753-61.
91. Baron MS, Vitek JL, Bakay RAE, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study Ann Neurol 1996;40:355-66.
92. Kishore A, Turnbull IM, Snow BJ, et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson's disease: six-month follow-up with additional 1-year observations. Brain 1997;120:729-37.
93. Schuurman PR, de Bie RMA, Speelman JD, Bosch DA. Bilateral posteroventral pallidotomy in advanced Parkinson's disease in three patients. Mov Disord 1997;12:752-5.
94. Pahwa R, Wilkinson S, Smith D, Lyons K, Miyawaki E, Koller WC. High-frequency stimulation of the globus pallidus for the treatment of Parkinson's disease. Neurology 1997;49:249-53.
95. Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998;121: 451-7.
96. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998;339: 1105-11.
97. Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease. Lancet 1997;350:1224.
98. Olanow CW, Koller W, Goetz CG, et al. Autologous transplantation of adrenal medulla in Parkinson's disease: 18-month results. Arch Neurol 1990;47:1286-9.
99. Lindvall O. Neural transplantation: a hope for patients with Parkinson's disease. Neuroreport 1997;8(14):iii-x.
100. Wenning GK, Odin P, Morrish P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997;42:95-107.
101. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-24.
102. Freeman TB, Olanow CW, Hauser RA, et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 1995;38:379-88.
103. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 1992;327:1549-55.
104. Deacon T, Schumacher J, Dinsmore J, et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 1997;3:350-3.
105. Miyoshi Y, Date I, Ohmoto T, Iwata H. Histological analysis of microencapsulated dopamine-secreting cells in agarose/poly(styrene sulfonic acid) mixed gel xenotransplanted into the brain. Exp Neurol 1996;138: 169-75.
106. Kang UJ. Potential of gene therapy for Parkinson's disease: neurobiologic issues and new developments in gene transfer methodologies. Mov Disord 1998;13:Suppl 1:59-72.